Biosimilar drugs breaking high-cost barrier to cancer immunotherapy
Recent changes in cancer care in India show an increase in immunotherapy prescriptions due to affordable biosimilars. Doctors report that the availability of cheaper versions of nivolumab has improved patient access to treatment. Research indicates that lower doses may be effective for Indian patients, contributing to the affordability of therapy. Although progress has been made, significant...
Key Takeaways
- Recent changes in cancer care in India show an increase in immunotherapy prescriptions due to affordable biosimilars.
- Doctors report that the availability of cheaper versions of nivolumab has improved patient access to treatment.
- Research indicates that lower doses may be effective for Indian patients, contributing to the affordability of therapy.
Recent changes in cancer care in India show an increase in immunotherapy prescriptions due to affordable biosimilars. Doctors report that the availability of cheaper versions of nivolumab has improved patient access to treatment. Research indicates that lower doses may be effective for Indian patients, contributing to the affordability of therapy. Although progress has been made, significant challenges remain regarding drug availability and hospital practices.
Original Publisher Attribution
This summary was curated from Times of India.